Follow
Martin Dreyling
Martin Dreyling
Professor of Medicine, University of Munich
Verified email at med.uni-muenchen.de
Title
Cited by
Cited by
Year
Revised response criteria for malignant lymphoma
BD Cheson, B Pfistner, ME Juweid, RD Gascoyne, L Specht, SJ Horning, ...
Journal of clinical oncology 25 (5), 579-586, 2007
52692007
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
ML Wang, S Rule, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ...
New England Journal of Medicine 369 (6), 507-516, 2013
18282013
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients …
W Hiddemann, M Kneba, M Dreyling, N Schmitz, E Lengfelder, R Schmits, ...
Blood 106 (12), 3725-3732, 2005
17072005
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma
AK Gopal, BS Kahl, S De Vos, ND Wagner-Johnston, SJ Schuster, ...
New England Journal of Medicine 370 (11), 1008-1018, 2014
12072014
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
E Hoster, M Dreyling, W Klapper, C Gisselbrecht, A Van Hoof, ...
Blood, The Journal of the American Society of Hematology 111 (2), 558-565, 2008
10782008
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
H Tilly, MG Da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, ...
Annals of oncology 26, v116-v125, 2015
10622015
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Eichhorst, T Robak, E Montserrat, P Ghia, CU Niemann, AP Kater, ...
Annals of Oncology 32 (1), 23-33, 2021
9282021
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆
M Dreyling, M Ghielmini, S Rule, G Salles, M Ladetto, SH Tonino, ...
Annals of Oncology 32 (3), 298-308, 2021
916*2021
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long …
G Lenz, M Dreyling, E Hoster, B Wörmann, U Dührsen, B Metzner, ...
Journal of Clinical Oncology 23 (9), 1984-1992, 2005
7832005
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with …
R Forstpointner, M Dreyling, R Repp, S Hermann, A Hänel, B Metzner, ...
Blood 104 (10), 3064-3071, 2004
7482004
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in …
M Dreyling, G Lenz, E Hoster, A Van Hoof, C Gisselbrecht, R Schmits, ...
Blood 105 (7), 2677-2684, 2005
7452005
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ...
The Lancet 393 (10168), 229-240, 2019
6802019
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ...
Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022
6442022
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective …
A Pastore, V Jurinovic, R Kridel, E Hoster, AM Staiger, M Szczepanowski, ...
The lancet oncology 16 (9), 1111-1122, 2015
6322015
Treatment of older patients with mantle-cell lymphoma
HC Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, ...
New England Journal of Medicine 367 (6), 520-531, 2012
6272012
Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
DA Eichenauer, BMP Aleman, M André, M Federico, M Hutchings, ...
Annals of Oncology 29, iv19-iv29, 2018
569*2018
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide …
R Forstpointner, M Unterhalt, M Dreyling, HP Böck, R Repp, H Wandt, ...
Blood 108 (13), 4003-4008, 2006
5532006
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
M Dreyling, W Jurczak, M Jerkeman, RS Silva, C Rusconi, M Trneny, ...
The Lancet 387 (10020), 770-778, 2016
5082016
Improvement of overall survival in advanced stage mantle cell lymphoma
A Herrmann, E Hoster, T Zwingers, G Brittinger, M Engelhard, P Meusers, ...
J Clin Oncol 27 (4), 511-518, 2009
5072009
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
P Pérez-Galán, M Dreyling, A Wiestner
Blood, The Journal of the American Society of Hematology 117 (1), 26-38, 2011
4802011
The system can't perform the operation now. Try again later.
Articles 1–20